InnoSer offers a unique in-vivo mouse assay that facilitates the testing of compounds aimed at treating Autosomal Dominant Polycystic Kidney Disease (ADPKD).
With a prevalence of 4 in 10.000, ADPKD is a relatively common genetic disorder. It has a profound disease burden on patients due to the formation of many fluid filled cysts in their kidneys. In addition, patients may also suffer from extrarenal complications such as liver cysts, pancreatic cysts, hypertension and cardiovascular abnormalities. In the majority of cases a mutation in Pkd1, the gene coding the polycystine-1 protein, underlies the disease.
To support the preclinical development of new drugs and therapies for ADPKD, InnoSer provides a genetically and phenotypically relevant model in the mouse.
The conditional (Tamoxifen) inducible kidney specific Pkd1 knockout mouse (Pkd1-cKO) was originally developed at the Leiden University Medical Centre and carries a Pkd1 gene that may be inactivated specifically in the kidney.
The key advantages of our ADPKD mouse model:
Multiple well established and validated models are available to meet your specific requirements in terms of clinical translatability, outcome measures and study duration (6 to 52 weeks). Assays are carried out by experienced staff at AAALAC facilities under SPF conditions.
Involved in InnoSer’s Scientific Advisory Board, Dr. Peters from Leiden University Medical Center focuses on insights into the genetic, pathophysiologic and functional mechanisms of inherited disorders, most notably Polycystic Kidney Disease.